HLA-C and small cell lung carcinoma: The cell lines we have identified as SMARCA4-UT have higher expression of immune and MHC antigen presentation genes than classical neuroendocrine SCLC-A and SCLC-N, raising the possibility that these tumors may respond to immunotherapy.